# Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter

**Jing-Yi Dang[#], Jun Fu[#], Zhao Zhang, Dong Liu, Debing Cheng, Hongbin Fan**

Department of Orthopedic Surgery, Xijing Hospital, the Fourth Military Medical University, Xi'an, China

[#]These authors contributed equally to this work.

*Correspondence to:* Hongbin Fan. Department of orthopedic surgery, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China. Email: fanhb@fmmu.edu.cn.

*Response to:* Wu J, Zhang M, Chen C, *et al*. Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin? Ann Transl Med 2022. doi: 10.21037/atm-21-7018.

Submitted Jan 19, 2022. Accepted for publication Mar 15, 2022.

doi: 10.21037/atm-2022-1

**View this article at:** https://dx.doi.org/10.21037/atm-2022-1

We thank for the comments from Wu *et al.* (1) on our research (2), comparison between trabectedin and doxorubicin in soft-tissue sarcomas. Reviewer Wu *et al.* said that in Table 1, we reported that 80 patients were included, which was inconsistent with the original study (3). In addition, Figure 6 showed the wrong data that the disease control rate of 54 of 75 patients in the experimental group and 41 of 39 patients in the control group lead to the inability to estimate the odds ratio (OR). We appreciate the suggestions. In *Table 1*, we listed the Hartmann's study (3) and we corrected the samples in Table 1 from (2). We now correct the Figure 6 of our research (2) since the mistake in typing the number (*Figure 1*).

They also said that the authors conducted the sensitivity analysis only by omitting Schöffski *et al.*'s study (4) and did not further exclude the other included studies. Since the sensitivity was conducted by removing each study in term and selecting the most obvious change one, we only reported the result omitting Schöffski *et al.*'s study, which is the most obvious change article. Other included researches had smaller influence on the $I^2$ value than Schöffski *et al.*'s study.

**Table 1** Characteristics of included trials (2)

| Author | Year | Type of study | Country | Intervention | n | Mean age (years) |
|---|---|---|---|---|---|---|
| Cesne | 2021 | RCT | France | Trabectedin | 52 | 66.5 |
| | | | | Best supportive care | 51 | 63.7 |
| Chawla | 2015 | RCT | USA | Trabectedin | 83 | 54 |
| | | | | Doxorubicin | 40 | 54 |
| Demetri | 2016 | RCT | USA | Trabectedin | 345 | 57 |
| | | | | Dacarbazine | 173 | 56 |
| Hartmann | 2020 | RCT | Germany | Trofosfamide | 75 | 70 |
| | | | | Doxorubicin | 39 | 70.5 |

**Table 1** (*continued*)

**Table 1** (*continued*)

| Author | Year | Type of study | Country | Intervention | n | Mean age (years) |
|---|---|---|---|---|---|---|
| Hensley | 2015 | RCT | UK | Gemcitabine-docetaxel + trabectedin | 53 | 54.8 |
| | | | | Gemcitabine-docetaxel + placebo | 54 | 56.2 |
| Jones | 2019 | RCT | UK | Trabectedin + G/D | 139 | 55 |
| | | | | Placebo + G/D | 70 | 54 |
| Martin-Broto | 2016 | RCT | Spain | Trabectedin + doxorubicin | 54 | 53 |
| | | | | Doxorubicin | 59 | 52 |
| Schöffski | 2021 | RCT | Belgium | Trabectedin | 40 | 59.5 |
| | | | | Dacarbazine | 40 | 56 |
| Seddon | 2017 | RCT | UK | Trabectedin | 129 | 56 |
| | | | | Dacarbazine | 128 | 55 |
| Tian | 2020 | RCT | China | Trabectedin | 24 | 38.58±14.01 |
| | | | | Doxorubicin standard-dose | 146 | 43.30±12.10 |




**Figure 1** Forest plot of relative risks (RRs) with corresponding 95% confidential intervals (CIs) in disease control rate (DCR) (2).

## Acknowledgments

*Funding:* None.

## Footnote

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Annals of Translational Medicine*. The article did not undergo external peer review.

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-2022-1/coif). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

## References

1. Wu J, Zhang M, Chen C, et al. Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin? Ann Transl Med 2022. doi: 10.21037/atm-21-7018.
2. Dang J, Fu J, Zhang Z, et al. Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis. Ann Transl Med 2021;9:1764.
3. Hartmann JT, Kopp HG, Gruenwald V, et al. Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. Eur J Cancer 2020;124:152-60.
4. Schöffski P, Toulmonde M, Estival A, et al. Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA". Eur J Cancer 2021;152:26-40.

**Cite this article as:** Dang JY, Fu J, Zhang Z, Liu D, Cheng D, Fan H. Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter. Ann Transl Med 2022;10(7):426. doi: 10.21037/atm-2022-1

 